Moors & Cabot Inc. Has $759,000 Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Moors & Cabot Inc. grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.7% in the third quarter, HoldingsChannel reports. The fund owned 5,818 shares of the life sciences company’s stock after buying an additional 95 shares during the period. Moors & Cabot Inc.’s holdings in Illumina were worth $759,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Empowered Funds LLC increased its stake in Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares during the period. Caprock Group LLC grew its holdings in shares of Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares in the last quarter. UMB Bank n.a. increased its position in shares of Illumina by 7.0% in the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after purchasing an additional 88 shares during the period. Integrated Advisors Network LLC increased its position in shares of Illumina by 2.0% in the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Finally, Carson Advisory Inc. raised its stake in Illumina by 3.8% in the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock valued at $360,000 after purchasing an additional 102 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 2.3 %

Shares of ILMN opened at $140.14 on Friday. The stock’s 50-day moving average price is $140.61 and its two-hundred day moving average price is $124.76. Illumina, Inc. has a 12 month low of $93.51 and a 12 month high of $156.66. The company has a market capitalization of $22.23 billion, a PE ratio of -14.07 and a beta of 1.13. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the company earned $0.33 earnings per share. The firm’s revenue was down 3.5% compared to the same quarter last year. On average, analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ILMN. Royal Bank of Canada increased their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Citigroup boosted their price objective on shares of Illumina from $155.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Piper Sandler decreased their price target on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, StockNews.com initiated coverage on Illumina in a research report on Thursday, August 29th. They set a “buy” rating for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.